Warning letter
Sunrise Pharmaceutical, Inc. [ARCHIVED]: warning letter of Jan 14, 2010
FDA warning letter 77504 · New Jersey District Office
Key facts
| Reference number | 77504 |
|---|---|
| Company | Sunrise Pharmaceutical, Inc. [ARCHIVED] |
| Subject | CGMP for Finished Pharmaceuticals/Adulterated/Misbranded |
| Issue date | Jan 14, 2010 |
| Posted date | Jan 14, 2010 |
| Issuing office | New Jersey District Office |
| Product type | Drugs |
| CFR sections cited | 341.72(b), 201, 201.66, 201.115, 201.150, 201.315, 341, 341.72, 211.68(b), 211.100(a), 211.115(a), 211.160(a) and 6 more |
| Inspection city | Rahway |
| Inspection ZIP | 07065 |
| Inspection start date | Jun 19, 2009 |
| Letter on fda.gov | web.archive.org |
At a glance
- 10–99 CFR sections cited
- OAI Linked inspection classification
- Yes Form FDA 483 issued
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About FDA warning letters
FDA warning letters notify a firm of significant regulatory violations found during an inspection or review and request prompt corrective action.
Source: U.S. Food and Drug Administration (FDA), Warning Letters · Source date: